Back to Search
Start Over
Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis.
- Source :
-
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2023 Oct; Vol. 19 (5), pp. e175-e182. Date of Electronic Publication: 2022 Sep 09. - Publication Year :
- 2023
-
Abstract
- Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have been approved for breast cancer (BC) treatment. Several trials suggested that arthralgia was reduced in patients treated with ET plus CDK4/6i compared with that in those with ET-alone. We aimed to compare arthralgia rates in BC patients treated with/without CDK4/6i. We reviewed randomized controlled phase II/III trials investigating CDK4/6i with ET in hormone receptor-positive and epidermal growth factor 2-negative BC. Publications were retrieved from PubMed from January 2014 to April 2021. We compared arthralgia rates between patients who were administered ET plus CDK4/6i (CDK4/6i group) and those treated with ET-alone (control group). We reviewed 12 trials that reported data on adverse effects for arthralgia. These trials included 17,440 patients (9255 in the CDK4/6i group and 8185 in the control group). The arthralgia rate in the CDK4/6i group was significantly lower than that in the control group (27.6% vs. 34.8%, p < .001), especially in early BC (28.8% vs. 37.3%, p < .001). These suggested that the arthralgia rate in patients treated with ET plus CDK4/6i was lower than that in patients treated with ET-alone and that CDK4/6i may decrease the arthralgia rate in BC patients treated with ET, especially in early BC.<br /> (© 2022 John Wiley & Sons Australia, Ltd.)
Details
- Language :
- English
- ISSN :
- 1743-7563
- Volume :
- 19
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Asia-Pacific journal of clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 36085411
- Full Text :
- https://doi.org/10.1111/ajco.13840